Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
2017 · Science · 4,526 citations
https://doi.org/10.1126/science.aan4236
H
Hussein A. Tawbi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
513
Papers
24.5K
Citations
61
h-index
145
i10-index
Hussein A. Tawbi is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immunotherapy and Immune Responses & CAR-T cell therapy research. The author has an h-index of 61, co-authored 437 publications.
ORCID: 0000-0003-1942-851XPapers by this author
worksRelatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
2022 · VUBIR (Vrije Universiteit Brussel) · 855 citations
Neoadjuvant relatlimab and nivolumab in resectable melanoma
2022 · Nature · 317 citations
https://doi.org/10.1038/s41586-022-05368-8
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
2020 · Annals of Oncology · 229 citations
https://doi.org/10.1016/j.annonc.2020.07.004
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
2022 · Nature · 129 citations
https://doi.org/10.1038/s41586-022-04833-8
SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma
2015 · Cancer · 105 citations
https://doi.org/10.1002/cncr.29858
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat